Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
Status:
Terminated
Trial end date:
2018-07-12
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well capmatinib, ceritinib, regorafenib, or entrectinib work
in treating patients with BRAF/NRAS wild-type stage III-IV melanoma. Capmatinib, ceritinib,
regorafenib, or entrectinib may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth.